Benzothia(DIA)zepine compounds for treatment of hbv and hdv
Patent Information
- Application Number
- HK62026124712
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-23
- Filing Date
- 2026-06-11
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Abstract This invention discloses benzothiazole (diazazo) compounds and pharmaceutical compositions thereof, as well as methods for treating hepatitis B virus (HBV) and hepatitis D virus (HDV) infections.
Claims
CLAIMS:
1. A compound of Formula II, or a pharmaceutically acceptable salt thereof, wherein: M is -CHF-, -CH(CH3)-, -CF(CH3)-, -CF2-, or -C(CH3)2-; Ra, Rband Rcare independently selected for each occurrence from the group consisting of hydrogen, C1-6alkyl, haloC1-6alkyl and C3-6monocycloalkyl; R1is OH, CH3, -C(O)NH2, -C(O)OH, -C(O)OC1-6alkyl, -P(O)(OH)2, -S(O)2OH orR2aand R2bare independently selected from the group consisting of hydrogen, halo, OH, methyl, ethyl and CH2OH; or R2aand R2btogether with the carbon atom to which they are attached form a C=CH2, C3-6monocycloalkyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl or 1,3-dioxanyl group, wherein the C3-6monocycloalkyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl or 1,3-dioxanyl group is optionally substituted with 1 to 3 independently selected from halo and methyl groups; R3is selected from the group consisting of hydrogen, halogen, cyano, RaRbN-, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkylthio, haloC1-4alkylthio, C3-7monocycloalkyl, C3-7monocycloalkyloxy, C3-7monocycloalkylthio, C3-7monocycloalkyl- CH2-thio, and C5-12bicycloalkylthio, wherein the C3-7monocycloalkyl, C3-7monocycloalkyloxy, C3-7monocycloalkylthio, C3-7monocycloalkyl-CH2-thio, and C5-12bicycloalkylthio group is optionally substituted with 1 to 3 halo groups; R4is haloC3-4alkyl; R5is phenyl, C3-7monocycloalkyl or C5-12bicycloalkyl, wherein the phenyl, C3-7monocycloalkyl or C5-12bicycloalkyl is optionally substituted with one to six substituentsindependently selected form the group consisting of halo, OH, CN, HOC(O)-, RaRbN-, RaRbNS(O)q-, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, haloC1-4alkyl, hydroxyC1-4alkyl-, RaRbNC1-4alkyl-, C1-4alkoxy, haloC1-4alkoxy, hydroxyC1-4alkoxy-, RaRbNC1-4alkoxy-, C1-3alkoxyC1-4alkyl-, haloC1-3alkoxyC1-4alkyl-, RaRbNC(O)-, C1-4alkylC(O)-, C1-4alkoxyC(O)-, C1-4alkylC(O)O-, C1-4alkylS(O)q-, C1-4alkylS(O)qNRc-, C1-6alkylS(O)qC1-4alkyl-, C1-4alkylC(O)C1-6alkyl-, and C1-6alkylC(O)OC1-4alkyl-; and q is independently selected for each occurrence from the group consisting of 0, 1 and 2.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein M is -CHF-.
3. The compound of claim 1 or 2, wherein Formula II is of Formula IIa, or a pharmaceutically acceptable salt thereof.
4. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R1is -C(O)OH.
5. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R1is -S(O)2OH.
6. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R1is -P(O)(OH)2,7. The compound according to any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R2aand R2bare independently selected from the group consisting of hydrogen, halo, OH and methyl.
8. The compound according to any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R2aand R2bare methyl.
9. The compound according to any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R2ais hydrogen and R2bare methyl.
10. The compound according to any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R2aand R2btogether with the carbon atom to which they are attached form a C=CH2, cyclopropyl, cyclobutyl, or oxetanyl group, wherein the cyclopropyl or cyclobutyl group is optionally substituted with 1-3 halo groups.
11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein R2aand R2btogether with the carbon atom to which they are attached form a C=CH2, cyclopropyl, cyclobutyl, or oxetanyl group.
12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R2aand R2btogether with the carbon atom to which they are attached form a cyclopropyl group.
13. The compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R3is haloC1-2alkyl.
14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein R3is CF3.
15. The compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R3is C5-12bicycloalkylthio.
16. The compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R3is haloC3-7monocycloalkylthio.
17. The compound according to any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R4is n-butyl substituted with 1 to 6 halo atoms.
18. The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein R4is n-butyl substituted with 1 to 6 F atoms.
19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R4is -CH2CH2CF2CH3.
20. The compound according to any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R4is n-propyl substituted with 1 to 6 halo atoms.
21. The compound of claim 20, or a pharmaceutically acceptable salt thereof, wherein R4is n-propyl substituted with 1 to 6 F atoms.
22. The compound of claim 21, or a pharmaceutically acceptable salt thereof, wherein R4is -CH2CH2CF3.
23. The compound according to any one of claims 1-22, or a pharmaceutically acceptable salt thereof, wherein R5is C3-7monocycloalkyl optionally substituted with one to six substituents independently selected form the group consisting of halo, OH, CN, HOC(O)-, RaRbN-, RaRbNS(O)q-, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, haloC1-4alkyl, hydroxyC1-4alkyl-, RaRbNC1-4alkyl-, C1-4alkoxy, haloC1-4alkoxy, hydroxyC1-4alkoxy-, RaRbNC1-4alkoxy-, C1-3alkoxyC1-4alkyl-, haloC1-3alkoxyC1-4alkyl-, RaRbNC(O)-, C1-4alkylC(O)-, C1-4alkoxyC(O)-,C1-4alkylC(O)O-, C1-4alkylS(O)q-, C1-4alkylS(O)qNRc-, C1-6alkylS(O)qC1-4alkyl-, C1-4alkylC(O)C1-6alkyl-, and C1-6alkylC(O)OC1-4alkyl-.
24. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein25. The compound according to an one of claims 1- 22, or a pharmaceutically acceptable salt thereof, wherein In certain embodiments, R5is phenyl optionally substituted with one to six substituents independently selected form the group consisting of halo, OH, CN, HOC(O)-, RaRbN-, RaRbNS(O)q-, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, haloC1-4alkyl, hydroxyC1-4alkyl-, RaRbNC1-4alkyl-, C1-4alkoxy, haloC1-4alkoxy, hydroxyC1-4alkoxy-, RaRbNC1-4alkoxy-, C1-3alkoxyC1-4alkyl-, haloC1-3alkoxyC1-4alkyl-, RaRbNC(O)-, C1-4alkylC(O)-, C1-4alkoxyC(O)-, C1-4alkylC(O)O-, C1-4alkylS(O)q-, C1-4alkylS(O)qNRc-, C1-6alkylS(O)qC1-4alkyl-, C1-4alkylC(O)C1-6alkyl-, and C1-6alkylC(O)OC1-4alkyl-.
26. The compound of claim 25, or a pharmaceutically acceptable salt thereof, wherein27. The compound of claim 25, or a pharmaceutically acceptable salt thereof, wherein R5is28. A pharmaceutical composition comprising a compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
29. A method of treating Hepatitis B (HBV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof.
30. A method of treating Hepatitis B (HBV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 28.
31. A method of treating Hepatitis D (HDV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof.
32. A method of treating Hepatitis D (HDV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 28.
33. A compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof, for use in therapy.
34. A compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof, for use as a medicament.
